Clinical Trials

BeiGene

IRB
Details
Info
23-008
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia (BGB-3111-402)